Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity (Unaudited)

v3.7.0.1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Paid-in Capital
Accumulated Other Comprehensive Income (loss)
Retained Deficit
Beginning Balance (in shares) at Dec. 31, 2015   108,322,250      
Beginning Balance at Dec. 31, 2015 $ 2,038,837 $ 1,082 $ 2,824,303 $ (55,177) $ (731,371)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (582,043)       (582,043)
Other Comprehensive Income 8,374     8,374  
Stock Compensation 6,561   6,561    
Issuance of Common Stock in public offerings, net of related expenses (in shares)   16,905,000      
Issuance of Common Stock in public offerings, net of related expenses 411,711 $ 169 411,542    
Issuance of Restricted Stock (in shares)   137,916      
Issuance of Restricted Stock 0 $ 2 (2)    
Ending Balance (in shares) at Jun. 30, 2016   125,365,166      
Ending Balance at Jun. 30, 2016 $ 1,883,440 $ 1,253 3,242,404 (46,803) (1,313,414)
Beginning Balance (in shares) at Dec. 31, 2016 158,829,816 158,829,816      
Beginning Balance at Dec. 31, 2016 $ 2,183,892 $ 1,588 3,946,442 (53,058) (1,711,080)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 260,391       260,391
Other Comprehensive Income 5,887     5,887  
Stock Compensation 5,233   5,233    
Issuance of Common Stock for the Vitruvian Acquisition, net of related expenses (in shares)   23,852,117      
Issuance of Common Stock for the Vitruvian Acquisition, net of related expenses 459,436 $ 239 459,197    
Issuance of Restricted Stock (in shares)   172,988      
Issuance of Restricted Stock $ 0 $ 1 (1)    
Ending Balance (in shares) at Jun. 30, 2017 182,854,921 182,854,921      
Ending Balance at Jun. 30, 2017 $ 2,914,839 $ 1,828 $ 4,410,871 $ (47,171) $ (1,450,689)